GlassScriptPhysician profile
Eleni Nackos
NPI 1023339819
$78,573.87
in general payments reported to CMS, 2019-2025
29 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $25K · 2021: $3,691 · 2022: $3,286 · 2023: $2,056 · 2024: $3,485 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $3,375 · Consulting Fee: $2,498 · Food and Beverage: $692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $3,375.00 |
| Consulting Fee | $2,497.50 |
| Food and Beverage | $692.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $47,576.30 | 2019-2021 | |
| Pfizer INC. | $13,385.24 | 2019-2024 | |
| Seagen INC. | $5,706.79 | 2019-2022 | |
| Immunomedics, INC. | $4,000.00 | 2020 | |
| Daiichi Sankyo INC. | $2,176.83 | 2020-2025 | Enhertu, Injectafer |
| Astrazeneca Pharmaceuticals LP | $2,036.07 | 2023-2025 | Enhertu, Tagrisso |
| Gilead Sciences, INC. | $1,651.92 | 2021-2022 | |
| Athenex Pharmaceutical Division, LLC | $1,250.00 | 2020 | |
| Abbvie INC. | $194.08 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $119.65 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $101.61 | 2021-2023 | Imbruvica |
| Celgene Corporation | $47.30 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $41.47 | 2019-2025 | |
| Glaxosmithkline, LLC. | $34.59 | 2023 | Ojjaara |
| Astellas Pharma US INC | $31.60 | 2025 | Vyloy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $28.64 | 2025 | |
| Janssen Biotech, INC. | $27.46 | 2025 | Erleada |
| Rigel Pharmaceuticals, INC. | $23.46 | 2021 | |
| Genentech USA, INC. | $22.27 | 2020 | |
| Sobi, INC | $20.85 | 2025 | |
| Beone Medicines USA, INC. | $20.19 | 2025 | Tevimbra |
| Eisai INC. | $18.04 | 2025 | |
| Merck Sharp & Dohme LLC | $16.55 | 2025 | Keytruda |
| Emd Serono, INC. | $15.32 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.12 | 2020 | |
| Acrotech Biopharma INC. | $12.52 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eleni Nackos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.